PRTC

PureTech Health PLC

PRTC, USA

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.

https://www.puretechhealth.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PRTC
stock
PRTC

Published on: 2025-12-14 09:00:08 moha.gov.vn

Read more →
PRTC
stock
PRTC

Market Moves: Why The Swatch Group AG UHRN stock could be top winner - 2025 Technical Overview & Community Consensus Trade Alerts moha.gov.vn

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-06-30)

Rating:

STRONG BUY

Target Price:

$46

Analyst Picks

Strong Buy

2

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

9.88

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

1.09

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-11.86 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-8.06 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2,503.34 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

High

0.49

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 1.47% of the total shares of PureTech Health PLC

1.

Birch Hill Investment Advisors LLC

(1.0041%)

since

2025/06/30

2.

Pentwater Capital Management LP

(0.2069%)

since

2025/06/30

3.

Portolan Capital Management, LLC

(0.115%)

since

2025/06/30

4.

Millennium Management LLC

(0.0987%)

since

2025/06/30

5.

Diadema Partners LP

(0.0303%)

since

2025/06/30

6.

Persistent Asset Partners Limited

(0.007%)

since

2025/06/30

7.

Strategic Advisers U.S. Total Stock

(0.0053%)

since

2025/07/31

8.

Fidelity Nasdaq Composite Index

(0.0032%)

since

2025/07/31

9.

JHancock International Small Company NAV

(0.0007%)

since

2025/05/31

10.

DFA International Core Equity 2 I

(0.0006%)

since

2025/07/31

11.

Atlantic Union Bankshares Corp

(0.0005%)

since

2025/06/30

12.

UBS Group AG

(0.0001%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Strong Deep Value(8)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(3)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.